NovAliX in drug discovery collaboration with Teijin Pharma

French company NovAliX has entered into a multi-target integrated drug discovery collaboration with Japanese drugmaker Teijin Pharma (TYO: 3401), the company revealed yesterday, marking the second deal with a Japanese company within a year.

This arrangement represents NovAliX’ first discovery collaboration with Teijin Pharma. Under the terms of the accord, NovAliX will receive technology access fees as well as further research funding payments. Financial details of the transaction were not disclosed.

Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX will initially use its protein biochemistry expertise in combination with its comprehensive biophysical technology platform. NovAliX will apply its proprietary Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterization of selected small molecule hit structures.